Biologic agents targeting the IL-1β pathway, such as the recombinant IL-1 receptor antagonist, anakinra, the neutralizing anti-IL-1β antibody, canakinumab, and the soluble decoy IL-1 receptor/IL-1 receptor accessory protein chimera, rilonacept, are currently approved for the treatment of a number of inflammatory conditions including RA, CAPS and gout50. This evidence concerns the gene IL1B and cryopyrin-associated periodic syndrome.